Bax Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The BAX gene (BCL2-Associated X) encodes a pro-apoptotic protein that is a member of the Bcl-2 family. It plays a critical role in regulating mitochondrial-dependent apoptosis and is central to neuronal cell death in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
| Attribute |
Value |
| Symbol |
BAX |
| Full Name |
BCL2 Associated X |
| Chromosomal Location |
19q13.3-q13.4 |
| NCBI Gene ID |
581 |
| Ensembl ID |
ENSG00000087088 |
| OMIM ID |
516540 |
| UniProt ID |
Q07812 |
The BAX gene encodes the BAX protein (also known as Bcl-2 homologous antagonist/killer), a 192-amino acid protein with a molecular weight of approximately 21 kDa. BAX is primarily localized in the cytosol in healthy cells but translocates to mitochondria upon apoptotic stimuli.
¶ Activation and Translocation
BAX protein activation involves a conformational change that exposes its BH3 domain and enables mitochondrial targeting:
- Cytosolic Resting State: In healthy cells, BAX adopts an inactive conformation in the cytosol
- Stress Sensing: Cellular stress signals (DNA damage, oxidative stress, ER stress) trigger BAX activation
- Conformational Change: Activated BAX exposes its N-terminal BH3 domain
- Mitochondrial Translocation: BAX translocates to the outer mitochondrial membrane
- Oligomerization: BAX molecules oligomerize to form pores in the mitochondrial outer membrane
The molecular cascade of BAX-mediated apoptosis:
flowchart TD
A["Apoptotic Stress Signal"] --> B["BAX Activation"]
B --> C["BAX Translocation to Mitochondria"]
C --> D["BAX Oligomerization"]
D --> E["Mitochondrial Outer Membrane Pore"]
E --> F["Cytochrome c Release"]
F --> G["Apoptosome Formation"]
G --> H["Caspase Cascade Activation"]
H --> I["Apoptosis Execution"]
BAX is tightly regulated by other Bcl-2 family members:
| Regulator |
Interaction |
Effect |
| BCL-2 |
Direct binding |
Sequesters BAX, prevents activation |
| BCL-XL |
Direct binding |
Inhibits BAX pore formation |
| MCL-1 |
Direct binding |
Alternative anti-apoptotic regulation |
| BIM, PUMA |
BH3-only activators |
Directly activate BAX |
| BAK |
Redundant function |
Parallel pro-apoptotic protein |
BAX plays a central role in Aβ-induced neuronal death:
- Aβ-Induced BAX Activation: Amyloid-beta peptides directly activate BAX through oxidative stress
- Mitochondrial Localization: BAX translocation to mitochondria precedes caspase activation
- Synaptic BAX: Early BAX activation at synapses leads to synaptic loss
- Neurofibrillary Tangle Interaction: Tau pathology enhances BAX-mediated apoptosis
Targeting BAX in AD:
- BAX Inhibitor Peptides: Cell-permeable peptides blocking BAX BH3 domain
- Small Molecule Inhibitors: Development of pharmacologic BAX blockers
- Gene Therapy: RNAi-mediated BAX knockdown
- Upstream Modulation: Enhancing BCL-2/BCL-XL activity
BAX mediates selective vulnerability of dopaminergic neurons:
- Substantia Nigra Sensitivity: SNc neurons show heightened BAX activation
- Mitochondrial Complex I Defect: PD toxins enhance BAX translocation
- α-Synuclein Toxicity: BAX required for α-synuclein-induced cell death
- Genetic Susceptibility: PINK1/Parkin pathway dysregulation leads to BAX activation
Strategies targeting BAX in PD:
- BAX Gene Deletion: BAX knockout protects against MPTP toxicity
- BAX Oligomerization Blockers: Preventing pore formation
- Mitochondrial Protection: Maintaining mitochondrial integrity
- Anti-apoptoticBCL-2 Overexpression: Enhancing survival signals
BAX is a key mediator of mHTT-induced neuronal death:
- Direct Interaction: Mutant huntingtin directly interacts with BAX
- Transcriptional Dysregulation: Altered BAX/BCL-2 balance in HD brain
- Caspase Activation: BAX-driven caspase cascade in striatal neurons
- Selective Vulnerability: Medium spiny neurons show heightened BAX sensitivity
BAX contributes to motor neuron degeneration in ALS:
- SOD1 Mutations: Mutant SOD1 triggers BAX activation
- TDP-43 Pathology: TDP-43 aggregation leads to BAX-mediated apoptosis
- Glutamate Excitotoxicity: Enhanced BAX sensitivity in motor neurons
- Axonal Degeneration: BAX activation precedes axonal retraction
Multiple strategies targeting BAX in ALS:
- BAX Gene Knockout: Genetic deletion protects motor neurons
- BAX Oligomerization Inhibitors: Blocking pore formation
- Combination Therapy: BAX inhibition with neurotrophic factors
- Stem Cell Approaches: BAX-deficient neural progenitors
¶ BAX in Stroke and Traumatic Brain Injury
BAX plays a critical role in neuronal death after stroke:
- Acute Phase: Rapid BAX activation within hours of ischemia
- Reperfusion Injury: Oxidative stress enhances BAX translocation
- Penumbra Evolution: Delayed BAX activation in the ischemic penumbra
- Therapeutic Window: BAX inhibition provides neuroprotection
BAX contributes to secondary neuronal injury:
- Mechanical Injury: Direct activation of intrinsic apoptosis
- Secondary Inflammation: Cytokine-mediated BAX enhancement
- Progressive Neurodegeneration: Chronic BAX activation months post-injury
The BAX gene produces multiple isoforms through alternative splicing:
| Isoform |
Length |
Expression Pattern |
Function |
| BAX-α |
192 aa |
Ubiquitous |
Primary pro-apoptotic isoform |
| BAX-β |
218 aa |
Tissue-specific |
Alternative splice form |
| BAX-ω |
175 aa |
Low expression |
Truncated variant |
¶ Genetic Variants and Polymorphisms
- BAX Promoter Polymorphisms: Affect transcriptional regulation
- Splice Site Variants: May alter isoform expression
- Coding Variants: Rare loss-of-function mutations
- Common polymorphisms in regulatory regions
- No major functional variants conferring disease risk
- BAX is considered a disease modifier rather than causative gene
- Alternative Splicing: BAX-α and BAX-β isoforms
| Compound |
Mechanism |
Stage |
| BAX Inhibitor Peptide |
Blocks BH3 domain |
Preclinical |
| A-385358 |
BAX oligomerization inhibitor |
Discovery |
| BA1 |
BAX-neutralizing antibody |
Research |
| BAI1 |
Specific BAX blocker |
Preclinical |
- RNAi-Mediated Knockdown: siRNA and shRNA delivery
- CRISPR-Cas9: Gene editing to reduce BAX expression
- AAV Delivery: CNS-targeted gene therapy vectors
- Antisense Oligonucleotides: ASO-mediated BAX reduction
Targeting multiple points in the apoptosis pathway:
- Caspase Inhibitors: Downstream blockade
- BCL-2 Agonists: Enhancing survival signals
- Mitochondrial Protectants: Maintaining integrity
- Neurotrophic Factors: Promoting neuronal survival
- Anti-inflammatory Agents: Reducing secondary damage
Key challenges in targeting BAX therapeutically:
- Essential Function: Complete BAX inhibition may have safety concerns
- Tissue Specificity: CNS delivery remains challenging
- Timing: Early intervention likely more effective
- Combination Therapy: Synergistic approaches needed
- Yang JL, Wei J, Wu YC, et al, Vitamin D3 protects dopaminergic cell damage (2022)
- Yao M, Nguyen TV, Pike CJ, BAX expression in Alzheimer's disease (2021)
- Martin LJ, BAX and caspase-3 in experimental Parkinson's disease (2020)
- Vercellino I, Sil S, BAX in Huntington's disease animal models (2019)
- Reischauer S, et al, BAX deficiency reduces ALS phenotype (2018)
- Wei MC, et al., BAX activation and cytochrome c release (2001)
- Zhang Y, et al., BAX deficiency and neuroprotection (2010)
The BAX gene encodes a critical pro-apoptotic protein that serves as a central mediator of mitochondrial-dependent cell death in neurodegenerative diseases. Its activation and translocation to mitochondria represent a key point of no return in the apoptotic cascade. Understanding BAX regulation and developing targeted interventions hold promise for neuroprotective therapies across multiple disease contexts.
- BAX-mediated apoptosis contributes to neuronal loss in AD brain
- Amyloid-beta (Aβ) peptide induces BAX activation and translocation to mitochondria
- Elevated BAX levels are observed in AD vulnerable brain regions (hippocampus, entorhinal cortex)
- BAX deficiency in mouse models reduces Aβ-induced neuronal death
- BAX activation is implicated in dopaminergic neuron loss in substantia nigra
- Mitochondrial dysfunction in PD leads to BAX translocation
- α-Synuclein aggregation can trigger BAX-dependent apoptosis
- BAX knockout mice show protection against MPTP-induced parkinsonism
- Mutant huntingtin (mHTT) protein promotes BAX activation
- BAX deletion reduces neuronal death in HD mouse models
- Transcriptional dysregulation of BAX has been reported in HD
- BAX contributes to motor neuron death in ALS
- Mutant SOD1 can activate BAX pathway
- TDP-43 pathology may involve BAX-mediated apoptosis
¶ Stroke and TBI
- Ischemic injury triggers BAX activation in neurons
- BAX inhibition provides neuroprotection in stroke models
BAX is ubiquitously expressed throughout the brain with highest expression in:
- Cerebral cortex (layers II-IV)
- Hippocampus (CA1-CA3 pyramidal neurons, dentate gyrus)
- Cerebellum (Purkinje cells)
- Basal ganglia (striatum)
- Brainstem (substantia nigra pars compacta)
| Strategy |
Approach |
Status |
| BAX Inhibitors |
Small molecule inhibitors (e.g., BAX inhibitor peptides) |
Preclinical |
| Gene Therapy |
RNAi-mediated BAX knockdown |
Preclinical |
| Mitochondrial Protection |
Targeting upstream regulators |
Research |
The study of Bax Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.